Similarly, in CKD, the treatment with ACE-Inhibitors reduced the risk of progression to end-stage disease by about 30% [48], while glifozines reduced by 30% the primary outcome (CKD progression or cardiovascular death) [49]. Here, ACE is linked to chronic kidney disease.